Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 02/24/22
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based TherapiesGlobeNewsWire • 02/23/22
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to DeclineZacks Investment Research • 02/17/22
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022GlobeNewsWire • 02/17/22
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with CancerGlobeNewsWire • 02/15/22
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022GlobeNewsWire • 01/06/22
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022GlobeNewsWire • 01/05/22
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune DiseasesGlobeNewsWire • 01/05/22
Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In HumansSeeking Alpha • 12/15/21
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary AngioedemaGlobeNewsWire • 12/13/21